Lycopene inhibits angiogenesis both in vitro and in vivo by inhibiting <scp>MMP</scp>‐2/u<scp>PA</scp> system through <scp>VEGFR</scp>2‐mediated <scp>PI</scp>3<scp>K</scp>‐<scp>A</scp>kt and <scp>ERK</scp>/p38 signaling pathways

Chen, Manling; Lin, Yu-Hsiu T.; Yang, Chang‐Hsien; Hu, Miao‐Lin

doi:10.1002/mnfr.201100683

Cited by 82 publications

(49 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, AXIIR siRNA was able to increase the expression of tissue inhibitor of metalloproteinase 2 (TIMP2), which was regularly accompanied with the suppression of MMP2 and MMP9 (Fig. 5C) [15]. Many studies had indicated that ERK1/2 and AKT were involved in activities of MMP2 and MMP9 [16,17,18].…”

Section: Resultsmentioning

confidence: 99%

SiRNA Directed Against Annexin II Receptor Inhibits Angiogenesis via Suppressing MMP2 and MMP9 Expression

Song

Pan

Sun

et al. 2015

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Annexin II receptor (AXIIR) is able to mediate Annexin II signal and induce apoptosis, but its role in angiogenesis remains unclear. This study tries to investigate the role of AXIIR in angiogenesis and the plausible molecular mechanism. Methods/Results: RNA interference technology was used to silence AXIIR, and the subsequent effects in vitro and in vivo were evaluated thereafter. Our data indicated that human umbilical vein endothelial cells (HUVECs) expressed AXIIR and knockdown of AXIIR significantly inhibited HUVECs proliferation, adhesion, migration, and tube formation in vitro and suppressed angiogenesis in vivo. Furthermore, AXIIR siRNA induced cell arrest in the S/G2 phase while had no effect on cell apoptosis. We found that these subsequent effects might be via suppressing the expression of matrix metalloproteinase 2and matrix metalloproteinase 9. Conclusion: AXIIR participates in angiogenesis, and may be a potential therapeutic target for angiogenesis related diseases.

show abstract

Section: Resultsmentioning

confidence: 99%

SiRNA Directed Against Annexin II Receptor Inhibits Angiogenesis via Suppressing MMP2 and MMP9 Expression

Song

Pan

Sun

et al. 2015

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…The induction of cell differentiation (52) via the restoration of gap junctions (57) has also been suggested. Other mechanisms include prevention of oxidative damage (58,59) , inhibition of angiogenesis (59,60) , induction of phase II enzymes (61)(62)(63) , interaction with growth factors and sex hormones (64) and the induction of nuclear receptors activation (65)(66)(67) . Lycopene has also been found to confer photoprotection (68) .…”

Section: Mechanistic Studiesmentioning

confidence: 99%

Cardiovascular benefits of lycopene: fantasy or reality?

et al. 2016

View full text Add to dashboard Cite

Epidemiological evidence indicates that high consumption of tomatoes and tomato-based products reduces the risk of chronic diseases such as CVD and cancer. Such potential benefits are often ascribed to high concentrations of lycopene present in tomato products. Mainly from the results of in vitro studies, potential biological mechanisms by which carotenoids could protect against heart disease and cancer have been suggested. These include cholesterol reduction, inhibition of oxidation processes, modulation of inflammatory markers, enhanced intercellular communication, inhibition of tumourigenesis and induction of apoptosis, metabolism to retinoids and antiangiogenic effects. However, with regard to CVD, results from intervention studies gave mixed results. Over fifty human intervention trials with lycopene supplements or tomato-based products have been conducted to date, the majority being underpowered. Many showed some beneficial effects but mostly on non-established cardiovascular risk markers such as lipid peroxidation, DNA oxidative damage, platelet activation and inflammatory markers. Only a few studies showed improvement in lipid profiles, C reactive protein and blood pressure. However, recent findings indicate that lycopene could exert cardiovascular protection by lowering HDL-associated inflammation, as well as by modulating HDL functionality towards an antiatherogenic phenotype. Furthermore, in vitro studies indicate that lycopene could modulate T lymphocyte activity, which would also inhibit atherogenic processes and confer cardiovascular protection. These findings also suggest that HDL functionality deserves further consideration as a potential early marker for CVD risk, modifiable by dietary factors such as lycopene.

show abstract

“…Urokinase-type plasminogen activator (uPA) binding to urokinae plasminogen activator receptor can activate the conversion of plasminogen to plasmin [22,23]. Therefore, the inhibition of VEGFR2 and MMPs/uPA system is regarded as a therapeutic strategy against angiogenesis [22,23]. However, effects of 2-DG on these molecules are unclear.…”

Section: Introductionmentioning

confidence: 99%

“…Pro-MMPs can be converted into a matured form of MMPs by plasmin, which is derived from plasminogen [21]. Urokinase-type plasminogen activator (uPA) binding to urokinae plasminogen activator receptor can activate the conversion of plasminogen to plasmin [22,23]. Therefore, the inhibition of VEGFR2 and MMPs/uPA system is regarded as a therapeutic strategy against angiogenesis [22,23].…”

Section: Introductionmentioning

confidence: 99%

The anti-angiogenic action of 2-deoxyglucose involves attenuation of VEGFR2 signaling and MMP-2 expression in HUVECs

et al. 2015

Self Cite

View full text Add to dashboard Cite

Lycopene inhibits angiogenesis both in vitro and in vivo by inhibiting MMP‐2/uPA system through VEGFR2‐mediated PI3K‐Akt and ERK/p38 signaling pathways

Abstract: Our data demonstrate the anti-angiogenic effect of lycopene both in vitro and in vivo. The anti-angiogenic activity of lycopene may involve inhibition of MMP-2/uPA system through VEGFR2-mediated PI3K-Akt and ERK/p38 signaling pathways.

Cited by 82 publications

References 50 publications

SiRNA Directed Against Annexin II Receptor Inhibits Angiogenesis via Suppressing MMP2 and MMP9 Expression

SiRNA Directed Against Annexin II Receptor Inhibits Angiogenesis via Suppressing MMP2 and MMP9 Expression

Cardiovascular benefits of lycopene: fantasy or reality?

The anti-angiogenic action of 2-deoxyglucose involves attenuation of VEGFR2 signaling and MMP-2 expression in HUVECs

Contact Info

Product

Resources

About